The combination resulted in the development of lung adenocarcinomas in mice induced by loss-of-function multi-genetic cancer mutations in LKB1 and p53 and HDR-mediated KrasG12D mutations.2 To date, the efficiency and safety of these delivery methods for the CRISPR/Cas9 system in NHPs remain to be determined. The gene discussed is TP53; the disease is lung adenocarcinoma.